It was announced on 15 November 2006 that Cobalt Laboratories Inc. has reached a patent litigation settlement with GlaxoSmithKline Plc. regarding its Âsumatriptan succinate tabletsÂ, the generic version of GlaxoSmithKline’s Imitrex, which is sold to treat migraine pain.
Cobalt Pharmaceuticals Inc. announced in a statement that the company may distribute a generic version in the U.S. by the first quarter of 2009 following the settlement which remains subject to government review.
This was just one term that was agreed between lawyers, but the statement did not provide additional details on the other terms of the settlement.
